Adial Pharmaceuticals Inc (ADIL) concluded trading on Wednesday at a closing price of $0.45, with 13.83 million shares of worth about $6.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.27% during that period and on June 11, 2025 the price saw a loss of about -23.77%. Currently the company’s common shares owned by public are about 8.72M shares, out of which, 8.57M shares are available for trading.
Stock saw a price change of -32.22% in past 5 days and over the past one month there was a price change of -25.89%. Year-to-date (YTD), ADIL shares are showing a performance of -55.17% which decreased to -63.42% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.51 but also hit the highest price of $3.00 during that period. The average intraday trading volume for Adial Pharmaceuticals Inc shares is 608.70K. The stock is currently trading -30.93% below its 20-day simple moving average (SMA20), while that difference is down -32.93% for SMA50 and it goes to -48.76% lower than SMA200.
Adial Pharmaceuticals Inc (NASDAQ: ADIL) currently have 8.72M outstanding shares and institutions hold larger chunk of about 6.59% of that.
The stock has a current market capitalization of $3.95M and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 1.99 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADIL, volatility over the week remained 14.09% while standing at 7.33% over the month.
Stock’s fiscal year EPS is expected to rise by 61.03% while it is estimated to increase by 5.66% in next year. EPS is likely to grow at an annualized rate of 41.31% for next 5-years, compared to annual growth of 34.05% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Rodman & Renshaw on November 14, 2024 offering a Buy rating for the stock and assigned a target price of $8 to it. Coverage by Maxim Group stated Adial Pharmaceuticals Inc (ADIL) stock as a Buy in their note to investors on October 30, 2018, suggesting a price target of $5 for the stock.
